Scottish Inflammatory Prognostic Score Predicts Survival in Metastatic Non-Small-Cell Lung Cancer Treated with Immune Checkpoint Inhibitors

Lung cancer is the leading cause of cancer mortality globally, with 2.5 million new cases and 1.8 million deaths, according to GLOBOCAN 2022 estimates. 1Non-small-cell lung cancer (NSCLC) accounts for approximately 85% of lung cancer cases. 2 Over the last decade, immune checkpoint inhibitors (ICIs) have transformed the treatment of solid tumors, resulting in substantial improvements in survival outcomes. 3nce nivolumab was approved in 2015, ICIs have become a cornerstone of NSCLC therapy, either as monotherapy or in combination with platinum-based chemotherapy. 4In a population-based analysis using the SEER database, Wang et al. 5 reported that the 5-year cancer-specific survival rate in NSCLC improved from 9.0% in the pre-immunotherapy era (2010-2014) to 14.3% in the immunotherapy era (2015-2020), thereby confirming the real-world survival benefit of ICIs in lung cancer.Despite these advances, both primary and acquired resistance to ICIs remain common, thereby limiting the durable benefit for a significant proportion of patients. 6ccordingly, there is a critical need for reliable biomarkers to refine patient selection for ICIs.